![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/spacer.gif)
salirasib A salicylic acid derivative with potential antineoplastic activity. Salirasib dislodges all Ras isoforms from their membrane-anchoring sites, thereby preventing activation of RAS signaling cascades that mediated cell proliferation, differentiation, and senescence. RAS signaling is believed to be abnormally activated in one-third of human cancers, including cancers of the pancreas, colon, lung and breast.
Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/spacer.gif)
Chemical structure name: | ![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/spacer.gif) | s-trans, trans-farnesylthiosalicylic acid | | ![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081025043003im_/http://www.cancer.gov/images/spacer.gif) |